Pursuant to 17 CFR 240.24b-2, confidential information has been omitted in places marked “* * *” and has been filed separately with the Securitites and Exchange Commission pursuant to a Confidential Treatment Application filed with the Commission....Credit Agreement • January 2nd, 2013 • Merus Labs International Inc. • Pharmaceutical preparations
This Credit Agreement dated as of July 10, 2012, (as amended, restated or otherwise modified from time to time, this “Agreement”) is made among MERUS LABS INTERNATIONAL INC., a corporation organized under the laws of British Columbia (“Borrower”), the Loan Parties named herein, PDL BIOPHARMA, INC. (the “Lender”), and PDL BIOPHARMA, INC., not individually, but as Agent (as defined below).
ASSET PURCHASE AGREEMENT between NOVARTIS PHARMA AG AND MERUS LABS LUXCO SARLAsset Purchase Agreement • January 2nd, 2013 • Merus Labs International Inc. • Pharmaceutical preparations
This ASSET PURCHASE AGREEMENT (“Agreement”) is made as of this 10th day of July, 2012 (“Closing Date”), by and between Novartis Pharma AG a company organized under the laws of Switzerland and located at Lichtstrasse 35, 4056 Basel, Switzerland (referred to as “Novartis”), and Merus Labs Luxco SARL, a company organized under the laws of Luxembourg (“Purchaser”), located at 208, Val des Bons Malades, Luxembourg L-2121, The Grand Duchy of Luxembourg. Novartis and Purchaser are each referred to individually as a “Party” and together as the “Parties.”
